EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source

Inclusion Criteria: * Age over 18 years * Patient has had an embolic stroke of undetermined source, defined as: * Ischaemic stroke or transient ischaemic attack diagnosed clinically + supporting radiological features on CT or MRI imaging * No clinically significant extracranial or intracranial atherosclerosis found on neck imaging * No evidence of prevalent cardioembolic source of embolism - atrial dysrhythmia, cardiac thrombus, prosthetic valve, cardiac tumours, mitral stenosis, recent MI, LVEF\<35%, valvular vegetations, or infective endocarditis AND * No other specific stroke aetiology identified (pro-thrombotic states, arteritis, dissection, drug abuse) * Patient has been referred for an implantable loop recorder implant to investigate possible atrial dysrhythmia * Ability to give written, informed consent Exclusion Criteria: * Prevalent atrial fibrillation or atrial flutter * Subsequent demonstration of a cardio-emoblic source * Pre-existent indication for SGLT2i including heart failure with a reduced ejection fraction and Type 1 or Type 2 diabetes mellitus * Contraindication to the commencement of SGLT2i including a history of, or risk factors for diabetic ketoacidosis, such as restricted food intake or a history of alcohol abuse * Hypersensitivity to the active substance or to any of the excipients of empagliflozin * Presence of alternate implantable cardiac devices such as a pacemaker or defibrillator, that would make ILR utilisation redundant * Any condition that may confound the results or interfere with participation such as dementia * An unwillingness to participate